Análise dos óbitos por AIDS no Brasil e sua relação com o uso de terapia antirretroviral no período de 2009 a 2013

• Ano de defesa: 2016
• Autor(a) principal: Freitas, Marcelo Araújo de
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal do Espírito Santo; BR; Mestrado em Doenças Infecciosas; Centro de Ciências da Saúde; UFES; Programa de Pós-Graduação em Doenças Infecciosas
• Palavras-chave em Português: Mortality; Highly active antiretroviral therapy; AIDS; Terapia antirretroviral de alta atividade; Síndrome de imunideficiência adquirida; HIV (Vírus); Mortalidade; Terapia; Doenças Infecciosas e Parasitárias; 61
• Link de acesso: http://repositorio.ufes.br/handle/10/4592

INTRODUCTION: Despite the introduction of universal access to antiretroviral therapy (ART) in Brazil 20 years ago, around 12,000 people still die of AIDSrelated causes every year. The aim of this study was to describe antiretroviral treatment of people living with HIV (PLHIV) who died of AIDS-related causes between 2009 and 2013. METHODS: We conducted a cross-sectional, populationbased study to establish the distribution of AIDS-related deaths among PLHIV between 2009 and 2013 in Brazil according to antiretroviral therapy status. Data were generated from a linkage process between Mortality Information System (SIM) and National ART dispensing database (SICLOM). Trends were modeled using linear regression analysis. RESULTS: A total of 61,425 AIDS-related deaths were registered in Brazil between 2009 and 2013. Median age at death was 41 years (IQR: 33-49) and 65.7% (40,337) of deaths were among men; 47.2% (29,004) of PLHIV who died during the study period never started treatment, 7.0% (4,274) had discontinued treatment, 15.9% (9,775) were on ART for six months or less and 29.9% (18,372) were on ART for more than six months. Only 1.3% of the PLHIV were on third-line ARV regimens at the time of death. CONCLUSIONS: Almost all of those who died of AIDS-related causes in Brazil did not get the full benefit of antiretroviral therapy. Even in a context of universal access to antiretroviral treatment for many years, robust health policies targeting gaps in HIV continuum of care are crucial to further reduce the impact of AIDS-related mortality in Brazil.